Fort Myers-based oncology testing services company NeoGenomics reported a $15 million net loss in the fourth quarter of 2024, a 7% year-over-year increase, according to an earnings report. That was a part of a $79 million loss for fiscal year 2024, an 11% decrease from 2023. Fourth-quarter consolidated revenue increased 11% to $172 million, marking nine consecutive quarters of double-digit revenue growth, while full-year consolidated revenue increased 12% to $661 million. Serving nearly 700,000 patients in 2024, average revenue per clinical test increased by 5% to $465. Company officials said the increases reflect higher value tests, including NGS and strategic reimbursement initiatives. Operating expenses for the fourth quarter were $96 million, an increase of $9 million. Operating expenses included higher compensation and benefit costs, as well as an increase in software support fees, company officials said.